Ipilimumab vs Montelukast

## Ipilimumab vs Montelukast: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Montelukast**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

**Montelukast**: Selective leukotriene D4 receptor antagonist.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Montelukast — 2.7-5.5 hours.

## Chemical Properties

**Molecular Formula**: Ipilimumab — N/A; Montelukast — C35H36ClNO3S.

**Molecular Weight**: Ipilimumab — N/A; Montelukast — 586.1800 g/mol.

**Type**: Ipilimumab — Antibody; Montelukast — Small molecule.